Politico, April 9th, 2022. The Biden administration’s contentious decision to only partially cover Aduhelm could reach well beyond the world of Alzheimer’s drugs, potentially affecting efforts to develop treatments for devastating diseases. “it was a defining moment for the White House and they passed with flying colors,” said Diana Zuckerman, the president of the National Center for Health Research. It “has sent a message to industry and to patient groups, and also to the FDA, that the standards had gotten too loose.”
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
FDA advisers to discuss ALS drug at Wednesday meeting
Politico, March 29, 2022. On March 30, FDA holds a highly anticipated advisory committee on neurological drugs to discuss a drug from Amylyx that aims to treat amyotrophic lateral sclerosis (ALS). Dr. Diana Zuckerman told Politico: “Did the FDA schedule an advisory committee meeting to placate patient advocates and other political pressure in the hope that the advisory committee would vote against it? Or is the FDA really considering approving it?”
Read More »Bella Hadid regrets getting a nose job at 14. How young is too young for plastic surgery?
USA Today, March 21, 2022: Model Bella Hadid regrets getting a nose job at 14. USA Today asks NCHR’s Dr. Diana Zuckerman how young is too young for plastic surgery, and we explain how it depends on the situation but that teenagers are unlikely to make the best decisions and parents need help from surgeons to say “let’s wait.”
Read More »Less Adderall, More Weed
Chronicle of Higher Education, February 28, 2022: Adderall, a stimulant medication often prescribed to treat attention deficit hyperactivity disorder, has been misused as a “study drug” on college campuses for years. According to the latest available annual national study, medications such as Adderall reached a 10-year low among college students in 2020.
Read More »High Praise, Condemnation for CMS Aduhelm Coverage Plan
Medscape Medical News, February 16, 2022: Medicare has received a key endorsement and considerable support for its plan to restrict payment for the controversial Alzheimer’s disease drug aducanumab (Aduhelm) — but also drew pleas from other groups for more generous reimbursement of the drug.
Read More »